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Summary
Objectives: To investigate, in chondrocyte cultures under conditions for maximizing responses in proliferation and proteoglycan (PG)
synthesis, the effects of glucosamine hydrochloride (GlcN.HCl) and glucosamine sulfate (GlcN.S) salts, N-acetyl glucosamine (GlcNAc),
and covalently substituted GlcN-X,Y,Z(SO4)n (general formula).
Methods: Bovine articular chondrocytes (BAC) were studied under anchorage-independent (AI, alginate beads) and anchorage-dependent
(AD, plastic surface) conditions. Differentiation markers were evaluated (e.g., cartilage-speciﬁc (VþC) ﬁbronectin). Varying concentrations
of GlcN.HCl, GlcN.S, GlcNAc and GlcN sulfated at positions 2, 3, 6, (2,3), (3,6) and (3,4,6), were tested. Cell proliferation, DNA
synthesis and [35S]-sulfate incorporation into newly synthesized PG were determined.
Results: Increasing GlcN.HCl or GlcN.S concentrations gave decreasing net PG synthesis. Compounds showed more pronounced effects in
AD cultures (expressing the VCþ ﬁbronectin isoform) compared to AI cultures ((VþC) isoform). Addition of GlcN.HCl or GlcN.S gave a
concentration-dependent decrease in BAC proliferation, partially prevented by glucose (Glc). GlcNAc was not inhibitory. Addition of GlcN-2-
SO4 or GlcN-2,6-diSO4 did not affect proliferation or DNA synthesis. The other GlcN-sulfates gave varying inhibitory effects, which for GlcN-3-
SO4 were reversed by inosine.
Conclusions: The free amino group of GlcN seems responsible for inhibition of chondrocyte proliferation and PG synthesis. These effects
were greater under higher concentrations of GlcN in AD vs AI conditions. GlcN.HCl behaves similarly to GlcN.S, but differential effects
with GlcN-X,Y,Z(SO4)n isomers were observed. Acetylation or sulfation of the GlcN amino group reverses or partially reverses, respectively,
anti-proliferative effects of GlcN. Sulfation of GlcN, at positions 3 and 6 results in complex effects on AC proliferation and PG synthesis.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Glucosamine, Chondrocyte, Osteoarthritis, Cartilage.
OsteoArthritis and Cartilage (2007) 15, 946e956
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2007.02.010
International
Cartilage
Repair
SocietyThe view that glucosamine (GlcN) and ‘‘glucosamine sul-
fate’’ are ‘‘nutriceutical’’ compounds, which can ameliorate
pain in osteoarthritis (OA) and possibly aid in the repair of
articular cartilage, is a controversial topic receiving a signif-
icant amount of attention. Several reviews, including an
older and an updated Cochrane protocol1, have been de-
voted to meta-analysis of currently available clinical trials
on orally administered ‘‘glucosamine sulfate’’ and GlcN
dealing with reductions of pain scores for OA of the knee.
In the recently updated protocol, the meta-analysis of the
reported effect of ‘‘glucosamine sulfate’’ on pain scores
was found to be less prominent than previously published1.
A number of preparations containing GlcN are available
‘‘over the counter’’ in North America, mostly sold as
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Received 22 June 2006; revision accepted 7 February 2007.94‘‘glucosamine sulfate’’. Chemical analysis of many of these
preparations has not yielded expected GlcN contents2.
Also, the term ‘‘glucosamine sulfate’’ used in the labels of
these and other preparations is confusing as it is not clear if
it means that they contain GlcN as an ionically bound sulfate
salt or if themolecule of GlcN is covalently bound to sulfate at
various positions around the sugar ring. In this paper, we will
avoid this confusion in terminology by using the term ‘‘glucos-
amine sulfate salt’’ (GlcN.S) to mean GlcN and an ionically
boundsulfatesalt,while for covalentlyboundSO4 toaspeciﬁc
carbon of the GlcN molecule standard chemical notation will
be employed, as for example GlcN-3-SO4 or GlcN-6-SO4.
Very recently contradictory results from large randomized
clinical trials from the United States (the National Institutes
of Health (NIH) Glucosamine/chondroitin Arthritis Interven-
tion Trial (GAIT)) and Europe have been verbally communi-
cated for OA of the knee, utilizing GlcN and GlcN.S
preparations, respectively (see Discussion). These clinical
trials raise the possibility that the contradictory results are
due to the different preparations used. Thus, testing GlcN,
GlcN.S and the covalently substituted glucosamine com-
pounds under in vitro conditions that permit uniform accessi-
bility to the cells and maximize effects (‘‘output’’) becomes
important in addressing this possibility.6
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trials with oral GlcN.S or GlcN is the metabolism of GlcN.
The serum levels of free GlcN after the ingestion of large
amounts of GlcN.S were below the limits of detection utiliz-
ing older methodology3. A recent, more sensitive method4
has been used to show that, in the rat, orally administered
GlcN is rapidly absorbed and cleared and that the gut,
rather than the liver, is responsible for the ﬁrst pass metab-
olism5. The levels of free GlcN in the serum and synovial
ﬂuid of the horse have also been reported recently to be
very low, probably below what would be required for phar-
macological effects6. These very low serum levels after
GlcN administration do not support the original rationale
for administration of GlcN in OA with cartilage loss, as a sub-
strate for new glycosaminoglycan (GAG) synthesis. Also, it
is not clear to what extent the GlcN molecule is incorporated
intact into complex carbohydrates or if it is ﬁrst deaminated
to glucose prior to incorporation.
Reported pharmacological effects of GlcN in experimen-
tal systems depend on the system tested. GlcN is toxic to
some rodent tumors7, possibly by competing with glucose
utilization, and the addition of GlcN to cultured adipocytes
induces insulin resistance, through mediating glucose-
induced desensitization of the transport system8. In carti-
lage explant systems, aminosugars in general, added in
high concentrations (maximal inhibition for mannosamine
at 1.35 mM and up to 10-fold greater concentrations for
GlcN), inhibited aggrecanase activity9. The addition of
GlcN and also mannosamine, in mM concentrations, in-
hibited degradation of aggrecan in cartilage explants, prob-
ably through inhibition of aggrecanase10. GlcN, added to
equine cartilage explants in high concentrations (25 mg/ml)
inhibited proteoglycan (PG) and metalloproteinase release
in the media11. Thus, the effects of the addition of GlcN to
cartilage explant cultures, at high concentrations, appear
to be largely mediated by inhibition of the degradation of
PGs, rather than stimulation of synthesis.
In recent papers utilizing cell culture systems, incubated
with GlcN or GlcN.S, the issues of whether effects on PG
synthesis are due to increased synthesis or decreased deg-
radation, as well as effects on cell numbers become critical.
For example, GlcN.S added in relatively low concentrations
to chondrocyte clusters from osteoarthritic cartilage resulted
in small increases of PG content of culture media and
clusters (on the basis of DNA) and similar effects DNA syn-
thesis, with increasing concentrations of GlcN.S12. How-
ever, it may be difﬁcult to differentiate between effects on
new PG synthesis, PG release or inhibition of degradation
of pre-synthesized PG, depending on protocols utilized, in
this type of culture systems. Also, GlcN.HCl (100 mg/ml)
suppressed PGE-2 production from OA chondrocytes and
matrix metalloproteinases from normal but not OA chondro-
cytes13. These authors emphasize also the importance of
deﬁning cells and conditions in these types of experiments.
Ina recent paper14wediscussed theadvantagesanddisad-
vantages of anchorage-independent (AI) and anchorage-
dependent (AD) chondrocyte culture systemswhenassessing
the effects of drugs, speciﬁcally GlcN-based compounds. AD
systems provide advantages in terms of uniform accessibility
of the drugs being tested, ability to determine cell kinetics
more reliably and may magnify comparative effects of drugs
on cell growth.However,AI systems tend to retain the cartilage
phenotype better. The type of culture system that best models
for damaged articular cartilage and areas of ﬁbrocartilagenous
remodeling is a more complex issue.
This paper addresses further the issue of putative differ-
ences between GlcN and GlcN.S and how the substitutionsof the free amino group by an acetyl or sulfate moiety affect
the functional ‘‘outputs’’ of cell culture systems derived from
articular cartilage. The functional ‘‘output’’ indicators exam-
ined consist of measurements of the prolifererative re-
sponses and anionic glycoconjugate synthesis (particularly
the PGs) for these systems. Speciﬁcally, we examine the
effect of GlcN.HCl, GlcN.S (an ‘‘over the counter prepara-
tion’’), N-acetyl glucosamine (GlcNAc), as well as several
GlcN-SO4 moieties with the SO4 covalently bound to differ-
ent positions of the GlcN molecule. The approach taken
here is pharmacological rather than physiological, so one
needs to consider the type of culture system which maxi-
mizes output responses between the analogues tested, uni-
form availability of the test compounds to the cells in the
culture, as well as the state of differentiation of the culture.
Materials and methods
MATERIALS
GlcN.HCl, GlcNAc and the GlcN-SO4 preparations,
namely GlcN-2-SO4, GlcN-3-SO4, GlcN-2,6-di-SO4, GlcN-
2,3-di-SO4, GlcN-3,6-di-SO4, GlcN-3.4.6-tri-SO4, were pur-
chased from Sigma, as were the other biochemicals (including
alginate lyase) used. GlcN.S was an ‘‘over the counter’’
material in tablet form said to contain 500 mg (per tablet),
manufactured by Swiss Herbal Remedies, ON, and veriﬁed
(see below) to contain approximately the stated amount of
GlcN base.
Sephadex G-10, analytical grade, was from Pharmacia,
Amersham Biosciences, QC. Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM), which contained no glucose, DMEM-
F12, a glucose-containing medium, fetal bovine serum
(FBS), Superscript II RNaseH reverse transcriptase, 100
base pair ladder and TA cloning kit were from GIBCO Invi-
trogen Corp., ON. Na2
35SO4 (speciﬁc activity 0.9 mCi/ml)
was from ICN Biomedicals Inc., OH. Taq DNA polymerase,
QIAEX II gel extraction kit and QIAPREP miniprep kit were
from Qiagen, ON. PCR primers and random hexamers were
from Cortec, ON.
SYNTHESIS OF GlcN.S
A solution of GlcN free base was prepared by adding
GlcN.HCl to one equivalent of NaOMe in methanol and stir-
ring for approximately 3 min. The precipitated NaCl is ﬁl-
tered off to give a clear solution. Dilute sulfuric acid (less
than one equivalent) is slowly added to the methanolic
solution with cooling and the precipitated GlcN sulfate is
ﬁltered off and washed with a small portion of methanol.
PURIFICATION OF GlcN.S FROM A COMMERCIAL
PREPARATION OF GlcN.S TABLETS
One commercial GlcN.S tablet was dissolved in phos-
phate buffered saline (PBS) and vortexed. The solution
was then centrifuged for 10-min at 300 g. Blue dextran
2000 was added to the supernatant. In order to separate
the GlcN moiety from salts and other compounds in the
commercial preparation, the supernatant was applied to
a Sephadex G-10 column pre-equilibrated with PBS and
10-min fractions collected (0.2 ml/min). Each fraction was
assayed for conductivity and every second was assayed
colorimetrically for GlcN using the method of Gardell15.
The elution proﬁle of GlcN with this column was compared
to that of GlcN.S. The identity of the eluted peaks was con-
ﬁrmed by 1H NMR (Bruker, 300 MHz).
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This was done as previously described14,16. Brieﬂy, artic-
ular cartilage was aseptically dissected from the convex
surfaces of metacarpophalangeal joints of freshly slaugh-
tered young adult cattle. The cartilage slices were washed
in PBS and digested overnight at 37C with 0.04% w/v col-
lagenase IV in PBS to obtain bovine articular chondrocytes
(BAC) as single cells.
AD cultures were established at high density in plastic
ﬂasks prior to seeding out at the densities indicated for
the various experiments. The cells were then sub-cultured
in 24- or 96-well plates (Linbro; ICN Biomedicals Inc., OH)
in either glucose free DMEM or DMEM-F12 (medium con-
taining 1 mg/ml glucose), 10% FBS and incubated over-
night in 5% carbon dioxide at 37 C. On the following day,
the medium was changed to fresh medium containing the
monosaccharide supplements of interest including GlcN,
GlcNAc, GlcN.S, the various GlcN-SO4, or Glc. The con-
centrations added for individual experiments are shown in
the ﬁgure legends or the ﬁgures. Cells were harvested by
trypsinization (AD) at various time intervals and the cell
number was determined using a Coulter counter (Coulter
Electronics Inc., FL).
Primary AI cultures in alginate beads were established
from the isolated chondrocytes at a seeding density of
0.2 106 cells per well, as described in14. The DMEM-
F12 growth medium, containing 10% FBS, included 3 mM
CaCl2 for enhanced alginate bead stability in culture. En-
capsulated chondrocytes were recovered from the alginate
beads as described by Barbero et al.31, and enumerated, as
for the AD cultures, at the end of each of 7, 14 and 21 day
incubation periods. Cultures remaining after 7 and 14 days
were re-fed with the same medium, after the original
medium had been removed.
DETERMINATION OF DEAD CELLS AND CELL CYCLE STUDIES
Cells were seeded at 5 103 cells/well (generally in 24
well plates) overnight, and the media were replaced with
fresh media containing the test material of interest. After 7
days the cells were harvested by trypsinization, washed
with 1 ml of 2% serum in PBS and centrifuged at 100 g
for 5 min. The cells were stained with propidium iodide for
5 min and analyzed on the ﬂow cytometer17. Brieﬂy, for
cell cycle analysis cells were seeded at 1.88 105 cells in
T-75 ﬂasks, in order to obtain enough cells for the analysis,
and maintained in Glc-free medium with the various addi-
tions, harvested at required time intervals, washed, pelleted
and suspended in 500 ml of ethanol. After 1 h, cells were
centrifuged and re-suspended in 0.1% Triton X-100, incu-
bated brieﬂy (10 min at 37 C), washed 2 with 2% serum
in PBS and re-suspended in 0.7 ml of the propidium iodide
solution (10% v/v Nonidet P-40, 10% w/v trisodium citrate,
10 mg/ml RNAase A, 1 mg/ml propidium iodide in PBS).
After 1 h incubation in the dark, at room temperature, the
cells were analyzed by ﬂow cytometry17, utilizing a Beckman
Coulter Elite instrument.
RADIOLABELING OF CHONDROCYTE CULTURES
For AD cultures, cells were re-plated in 6-, 24- or 96-well
plates, at densities dictated by the protocol used14,16,18. For
labeling the GAGs of the PGs cells were plated at relatively
high density, the media were replaced with fresh media con-
taining test compounds of interest and radio-labeled with10 mCi/ml [35S]-sulfate and after 4 days of incubation at
37 C, both the media and cells were harvested. Speciﬁc
protocols are given in legends to ﬁgures. The cells were
counted as described (to obtain net PG synthesis per
cell), and the media stored at 20 C.
DNA synthesis was measured as previously described14.
Brieﬂy, chondrocytes were plated in the 96-well plates
(1000 cells/well) and, on the following day (day 1), the me-
dia were replaced with fresh DMEM containing test mate-
rials of interest. Three or seven days later, the cells were
pulse labeled with [3H]-thymidine (0.3 mCi/well; ICN) for 6
and 18 h in the same culture conditions. After labeling, the
cells were washed and the radioactivity incorporated into
the cells was measured.
The AI cultures were radiolabeled in a similar fashion, ex-
cept that the [35S]-sulfate labeling was for days 1e7, 8e14
and 15e21, in order to obtain data for the cumulative radio-
activity incorporated into the PGs.
QUANTIFICATION OF RADIOLABEL INCORPORATED INTO
NEWLY SYNTHESIZED ANIONIC GLYCOCONJUGATES
The Alcian blue precipitation method was employed
as previously described16,18,19. Brieﬂy, the samples
(20 ml media from AD cultures and 100 ml media or dis-
solved beads from AI cultures) were applied in triplicate
on cellulose polyacetate electrophoresis strips, dried and
stained for 1 h at room temperature, in 0.05% w/v Alcian
blue in 30 mM MgCl2, 1% v/v acetic acid, 10% v/v etha-
nol. The strips were destained, dried and appropriate
areas were cut out and suspended in 5 ml non-aqueous
scintillation ﬂuid (Betamax; ICN) and the radioactivity
was quantiﬁed by liquid scintillation.
For AI cultures, the Alcian blue precipitation was pre-
ceded by an alginate lyase digestion step, as the alginate
partially interferes with the dye binding: the medium and dis-
solved beads were digested for 3 h at 37 C for 3 h with
0.5% w/v alginate lyase in the presence of proteinase
inhibitors.
PHENOTYPIC EXPRESSION OF AD AND AI CHONDROCYTE
CULTURES
Collagen types and ﬁbronectin isoforms were determined
by previously described methods14, 20e22. Brieﬂy, total RNA
was isolated from the cultured chondrocytes and RNA qual-
ity was assessed on a denaturing formaldehyde agarose
gel. First strand complementary DNA (cDNA) was synthe-
sized from total RNA with Superscript RNaseH reverse
transcriptase using random hexamers. The appropriate
cDNAs were ampliﬁed for 35 PCR cycles using pairs of
thin-layer chromatography puriﬁed primers and Qiagen
Taq polymerase. The ﬁbronectin cDNA in the VC region
was ampliﬁed using primers designed by Macleod et al.21.
Collagen I cDNA was ampliﬁed using the primers GCCAA-
GAAGAAGACATCC and GGTGATTCCTGGCCTTC. Re-
action products were resolved in agarose gels and
visualized by staining with ethidium bromide. For identiﬁca-
tion of PCR bands by sequencing, ampliﬁed cDNA frag-
ments were puriﬁed by agarose gel electrophoresis,
isolated by the QIAEX II gel extraction kit and ligated into
pCR2.1 using the Invitrogen TA cloning kit. Recombinant
plasmid was transformed into INVaF cells, and puriﬁed us-
ing a Qiagen Qiaprep miniprep kit. DNA sequence was de-
termined by Cortec with an automated PCR-based system
using ﬂuorescent labels.
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The data for the cell counts were averages from three
replicate wells, each counted in triplicate, from at least
three experiments. For the radiolabel incorporation stud-
ies, the analysis was done in triplicate from individual rep-
licate wells. Results are expressed as the meansSD.
Data were analyzed with one way analysis of variance
using the statistical package INSAT (GraphPad, San
Diego, CA).
Results
INCREASING CONCENTRATIONS OF GlcN TO CHONDROCYTE
CULTURES RESULTS IN DECREASED PG SYNTHESIS, BUT
THE MAGNITUDE OF THE RESPONSE IS LESS
UNDER AI COMPARED TO AD CONDITIONS
Figure. 1A and B shows the cumulative radioactivity, with
time, incorporated into the PG of the alginate beads and in
the culture medium, respectively. Much more labeled PG is
retained in the beads [Fig. 1(A)] than accumulates in the
medium fraction [Fig. 1(B)]. Within the beads, the highest
concentration of added GlcN (5 mM) resulted in the greatest
inhibition of cumulative net PG synthesis [Fig. 1(A)]. How-
ever, for the PG retained within the beads, the relative de-
crease in incorporation was not proportional to the
concentrations of GlcN added to the medium, even at the
end of the three week period. For the labeled PG appearing
in the medium outside the beads [Fig. 1(B)], also the highest
concentration of GlcN resulted in the largest inhibition of cu-
mulative net PG synthesis, but the lower concentrations of
GlcN resulted in only small (not signiﬁcant) inhibitions.
There were no signiﬁcant changes after 1 week of culture.
None of the GlcN concentrations tested resulted in stimula-
tion of PG synthesis.
When the data for cumulative, net PG synthesis is cor-
rected for the number of cells within the beads, more com-
plex patterns were apparent, as a result of inhibition of cell
proliferation by increasing concentrations of GlcN (data not
shown). This inhibition of cell proliferation was apparent at
week 2, resulting in a ‘‘ﬂattening out’’ of the net cumulative
PG synthesis per cell within the beads at weeks 2 and 3,
for the cultures to which the various concentrations of
GlcN had been added. However, for the media fraction
net cumulative PG synthesis per cell was approximately
linear for all cultures and at 3 weeks there was a propor-
tional decrease in labeled PG with increasing concentra-
tions of GlcN.
Figure. 1C shows the effect of increasing concentrations
of GlcN added to AD chondrocyte cultures, on net PG syn-
thesis. Highly signiﬁcant decreases in PG synthesis are
seen at GlcN concentrations greater than 0.1 mM. The re-
sults shown are expressed on a per cell basis. A very sim-
ilar pattern of PG synthesis is apparent if the results are not
corrected for cell number, since in the protocol used, where
the cells were plated was at relatively high cell densities,
cell proliferation was minimally inhibited by GlcN (data not
shown).
Comparison of Fig. 1A and B with Fig. 1C suggests that
the AD system represents a more sensitive assay, com-
pared to the AI system, because of the larger responses
of PG synthesis (higher sensitivity of output) and the relative
simplicity of the former. However, with subculture, AD chon-
drocyte culture systems tend to ‘‘de-differentiate’’, necessi-
tating characterization of the culture systems employed, in
terms of some of the cartilage and ﬁbrocartilage phenotypic
markers.0
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Fig. 1. (A, B) Cumulative net synthesis of PG by chondrocytes cul-
tured in alginate beads with increasing concentrations of GlcN.
GlcN, at 0 (-), 0.05 (B), 0.1 (C), 0.5 (6) and 5 (:) mM,
was added to the media of AI alginate bead cultures and was
present throughout the 3 weeks. The cultures were labeled with
[35S]-sulfate for successive 1 week periods. The labeled PGs
were precipitated on cellulose acetate by Alcian blue (after disso-
ciation of the beads and digestion of the medium and dissolved
beads with alginate lyase) at the end of each labeling period
and quantiﬁed, as described in the Methods. The PG accumula-
tion in the beads [Fig. 1(A)] and media [Fig. 1(B)] over 3 weeks
are shown. (C) Net synthesis of PG by AD chondrocyte cultures
with increasing concentrations of GlcN. Semi-conﬂuent AD chon-
drocyte cultures were fed with media supplemented with the
concentrations of GlcN indicated, as well as [35S]-sulfate
(10 mCi/ml). The cells were incubated for a further 4 days, the me-
dia harvested and the cells enumerated. The radiolabel incorpo-
rated into the newly synthesized PGs was determined by the
Alcian blue precipitation method.
950 D. E. Terry et al.: Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesisFigure. 2A illustrates that the cartilage-speciﬁc FN isoform,
(VþC) (800 bp), is the predominant ﬁbronectin (FN) iso-
form expressed by chondrocytes freshly isolated from bovine
cartilage in AD cultures (lane 2). With increasing time in AD
culture (lanes 3e6), the cartilage-speciﬁc FN isoform de-
creases and the (VþC)þ (1600 bp) and VCþ (1200 bp) iso-
forms increase. Fig. 2B illustrates that collagen I is not
expressed by freshly isolated chondrocytes in AD cultures
(lane 2), but with increasing time in AD culture (lanes 3e6)
collagen I expression increases. For the AI system, reverse
transcription-PCR (RT-PCR) of RNA isolated from chondro-
cytes, sub-passaged frommonolayer, after 1week in alginate
beads, showed the cartilage-speciﬁc FN isoform (VþC) to
be predominant, and no detectable type I collagen I was
expressed (data not shown).
The higher sensitivity and output range of the AD, com-
pared to the AI, system was also seen in proliferation as-
says14. If the cells were plated at low density (AD) and
the test compounds are added at the beginning of cell pro-
liferation, relatively large and signiﬁcant differential effects
were observed between compounds. Under these condi-
tions, data for both proliferation rates as well as ﬁnal cell
densities (density-dependent inhibition of growth) can be
obtained and, presumably, all cells in the culture are ex-
posed to uniform concentrations of the test compounds. In
subsequent experiments, therefore, AD proliferative assays
were employed for the comparative testing of the GlcN-
based compounds.
THE ADDITION OF GlcN BUT NOT GlcNAc TO CULTURE MEDIA
INHIBITS CHONDROCYTE PROLIFERATION
Figure. 3A shows that the addition of 0.5 mM GlcN to cul-
tures resulted in a lower ﬁnal cell density, and an apparently
lower rate of proliferation, at least between days 4 and 8.
There was no evidence of cell detachment in theGlcN-treated cultures, compared to the other conditions.
The addition of 0.5 mM GlcNAc did not affect the rate of
growth or ﬁnal cell density, over the 10 day growth period
and was identical to controls. Preliminary experiments
had indicated that the addition of 0.5 mM HCl to the medium
had no effect on proliferation, and the cells responded nor-
mally to increasing concentrations of serum, with 10% supple-
mentation (used in the experiments) giving intermediate rates
of proliferation between the 5% and 10% supplementations.
THE GlcN-DEPENDENT INHIBITION OF PROLIFERATION
IS PARTIALLY REVERSIBLE
In order to test if the inhibition to proliferation of BAC was
reversible, cultures were grown for 10 days under the same
conditions as for Fig. 3A, and then re-fed with media of the
same composition, except for one set of the GlcN-fed cul-
tures that were re-fed with medium supplemented with
GlcNAc (Fig. 3B). Re-feeding cultures initially fed with
GlcN, with fresh GlcNAc-supplemented medium, resulted
in a greater cell density than re-feeding corresponding cul-
tures with fresh medium containing GlcN. However, the
higher ﬁnal cell densities of control cultures, or cultures ini-
tially fed with GlcNAc, were not achieved in cultures initially
fed with GlcN and then re-fed with GlcNAc. The latter did
show a sharp increase in the rate of proliferation after re-
feeding, between days 10 and 12.
GlcN INHIBITION OF PROLIFERATION IS DOSE-DEPENDENT
AND AFFECTS MOSTLY THE FINAL CELL DENSITIES
ACHIEVED
Varying the initial concentration of GlcN (0.1e1.0 mM) that
the cultures were fed with, differentially affected the prolifera-
tive responses of the chondrocytes (Fig. 3C). Little difference
in the initial rate of proliferation was observed (up to day 2),1
A B
2 3 4 5 6
1200bp
800bp
Fig. 2. (A, B) Expression of the cartilage-speciﬁc ﬁbronectin isoform (VþC) and type I collagen in AD primary cultures. Lane 1 shows an 100
base pair ladder; lanes 2e6 show the RT-PCR of RNA isolated from chondrocytes after different times in culture: lane 2 (day 0); lane 3 (day 5);
lane 4 (day 9); lane 5 (day 12); lane 6 (day 15). The expression of the cartilage-speciﬁc ﬁbronectin isoform (VþC) at 800 bp is shown in (A)
and type I collagen in (B).
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Fig. 3. (A) The effect of re-feeding AD cultures with media supplemented with GlcN or GlcNAc supplementation on chondrocyte kinetics: chon-
drocytes were plated at the initial cell density indicated and incubated with the glucose-containing medium, DMEM-F12, 10% FBS and per-
mitted to attach overnight. The cells were then re-fed with the same medium either with no supplementation (control), or supplemented with
0.5 mM of GlcN or 0.5 mM GlcNAc. At the time intervals indicated, the cells were harvested and counted using a Coulter counter. Designations
are control (-), GlcN (C), GlcNAc (B). (B) The effect of replacing the medium of conﬂuent AD cultures with fresh medium containing different
GlcN or GlcNAc. The BAC were grown for 10 days before the medium was removed and replaced with fresh medium with the same supple-
ments, except one set of cultures which was originally fed with DMEM-F12, 10% FBS with 0.5 mM GlcN was replaced with DMEM-F12, 10%
FBS, 0.5 mM N-GlcNAc, designated by: ,. Other designations are as for Fig. 3A. (C) The effect of varying GlcN concentration on rates of
proliferation and ﬁnal cell densities. AD cultures of chondrocytes were incubated in DMEM-F12, 10% FBS, in the presence of GlcN at
1.0(:), 0.5 (-), or 0.1 mM (¤) GlcN, following the protocol of (A). At the time intervals indicated, the cells were harvested and enumerated.
(D) The effect of glucosamine concentration on BAC proliferation in the presence and absence of glucose: BAC were incubated with either
10% FBS, DMEM (-) or the glucose-containing medium, DMEM-F12. 10% FBS (B). BAC were harvested and counted with a Coulter
counter after incubation for 6 days in DMEM  glucose in the presence of increasing concentrations of glucosamine.but therewere clear, statistically signiﬁcant differences, in the
ﬁnal cell densities achieved in a dose-dependent fashion.
The shape of the growth curves suggests density-dependent
inhibition of growth behavior, for each GlcN concentration.
There was no decline in cell numbers toward the end of the
growth period at any concentration tested.
THE ANTI-PROLIFERATIVE EFFECT OF GlcN IS MODULATED
BY THE PRESENCE OF Glc
A range of concentrations of GlcN were tested for a 7 day
growth period. In the presence of Glc, increasing concen-
trations of GlcN from 0 to 2.5 mM showed only a slight de-
crease in proliferation, but there was a much sharper
decline at concentrations from 2.5 to 10 mM [Fig. 3(D)].However, in the absence of Glc, increasing GlcN concen-
trations (0e10 mM) resulted in essentially a linear decrease
in cell proliferation over the same growth time period.
Determination of the viability of chondrocytes, by the
apoptosis stain with propidium iodide described in the
Methods, showed that chondrocyte cultures in DMEM, with
0.5 mg/ml glucose, contained 6.8 0.8%non-viable, stained
cells at maximal cell densities achieved. GlcN containing cul-
tures generally demonstrated increasing proportions of
stained cells, but this effect appeared to be complex and
not speciﬁc to GlcN. Diluting the amino acid and other nutri-
ents in the media two-fold resulted in a decline in the propor-
tion of stained cells (3.8 0.2%), but the absence of glucose
in the standard media the percentage of stained cells in-
creased (10.7 0.8%). Cell cycle analysis suggested that,
952 D. E. Terry et al.: Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesisin general, lower ﬁnal cell densities were associated with pro-
longed S and G2þM phases, leading to a lower number of
cells in the G1 phase (data not shown).
THE GlcN ISOLATED FROM A NUTRICEUTICAL SOURCE OF
GlcN.S ALSO INHIBITS CHONDROCYTE PROLIFERATION
IN A DOSE-DEPENDENT FASHION
Sephadex G-10 chromatography was undertaken for
GlcN.HCl and the commercial preparation GlcN.S
[Fig. 4(A)]. The overlapping elution proﬁles demonstrate
that the commercial preparation of GlcN.S behaves as a sul-
fate salt of GlcN. The identity of the GlcN Sephadex G-10
peak from the commercial preparation of GlcN.S was con-
ﬁrmed by NMR, further indicating that the preparation con-
tained GlcN and not a covalent GlcN-SO4 compound (data
not shown). The effect of synthesized GlcN.S on the prolifer-
ation of AD chondrocyte cultures was also studied [Fig. 4(B)].
It is apparent that GlcN.S inhibits the proliferation of AD chon-
drocytes in a dose-dependent manner, similar to GlcN.HCl.
COVALENTLYBOUNDGlcN-SO4COMPOUNDSHAVEDIFFERENTIAL
EFFECTSONCHONDROCYTE PROLIFERATION
AND DNA SYNTHESIS, DEPENDINGON THE
POSITIONOF THE BOND
A number of the available GlcN-SO4 compounds were
evaluated for their effect on chondrocyte proliferation
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Fig. 4. (A) Elution of GlcN and a commercial preparation of GlcN.S
from Sephadex G-10. The concentration of GlcN was assayed in
the column efﬂuent as described in the Methods. The elution proﬁle
of GlcN, as GlcN.HCl (:) and the commercial preparation of
GlcN.S (,) are indicated. (B) Effect of synthesized GlcN.S on
chondrocyte proliferation. GlcN.S was prepared as described under
Methods and assayed, at the concentrations indicated, for its effect
on chondrocyte proliferation, following the method described in (A),
except that the incubation period was 7 days (open bars).under AD conditions [Fig. 5(A)]. The media utilized did
not contain Glc, because of the linear response of GlcN
previously observed for Glc-free but not Glc-containing
media, as shown above in Fig. 3D. No signiﬁcant effects
on chondrocyte cell densities, after 4 days of growth,
were observed with the addition of 1 mM of GlcN-2-SO4,
GlcN-2,6-di-SO4 or GlcN-6-SO4. There were relatively (to
GlcN) small but signiﬁcant inhibitions of cell growth with
the addition of GlcN-2,3-di-SO4 and GlcN-3-SO4. The ad-
dition of GlcN-6-SO4 resulted in cell numbers that were
somewhat smaller than GlcN-2,6-di-SO4 but the difference
was not signiﬁcant. GlcN-3,4,6-tri-SO4 was also tested, in
a subsequent experiment (not shown) and it exhibited an
inhibitory effect similar to GlcN-2,3-di-SO4. Cell numbers
were also evaluated after 8 days of growth and similar
differential effects as the 4 day growth experiment were
obtained (not shown).
The addition of adenosine 50-triphosphate (ATP) and ino-
sine to the cultures, as an exogenous additional metabolic
energy source. However, this addition failed to reverse
the GlcN-mediated inhibition of chondrocyte proliferation
(data not shown). Since a relatively small but signiﬁcant in-
hibition of proliferation was noted with supplementation of
the media with the -SO4 substitutions of GlcN either at the
3 position, or the 2,3 positions (but not at the 2 position
alone, the 6 position alone or a combination of 2 and 6),
the effects of ATP and inosine were further studied in cul-
tures supplemented with GlcN-3-SO4. While the addition
of various concentrations of ATP failed to prevent the
GlcN-3-SO4 associated inhibition of chondrocyte prolifera-
tion, 2.5 mM inosine completely reversed GlcN-3-SO4 medi-
ated inhibition on cell proliferation [data for proliferation not
shown, see Fig. 5(B) for DNA synthesis].
For the DNA synthesis experiments, chondrocyte cul-
tures were maintained for 3 or 8 days and labeled with
[3H]-thymidine for either 6 or 18 h. The data for the 8-day
cultures for 18 h of labeling are shown in Fig. 5B. Virtually
no [3H]-thymidine was incorporated into chondrocyte DNA
in the presence of added GlcN. This inhibition of DNA syn-
thesis could not be reversed either with ATP or inosine
(added at the maximal concentrations that did not signiﬁ-
cantly adversely affect or stimulate chondrocyte prolifera-
tion). There was no signiﬁcant effect on chondrocyte DNA
synthesis by the addition of GlcN-2-SO4 or GlcN-2,6-di-
SO4 (as for the proliferation studies, Fig. 9), while the addi-
tion of GlcN-2,3-SO4 or GlcN-6-SO4 did signiﬁcantly inhibit
DNA synthesis in this assay. The relatively small inhibitory
effect on DNA synthesis by GlcN-3-SO4 was reversed by
2.5 mM inosine (as was the case for the cell proliferation
studies).
When DNA synthesis was studied earlier during cell cul-
ture (3 days of growth), with the 6 h labeling protocol, GlcN-
3-SO4, GlcN-2,3-SO4 or GlcN-6-SO4 (and GlcN) showed
signiﬁcant inhibitory effects. However, for the same period
of growth with an 18 h labeling period, all the SO4 ana-
logues (and GlcN) showed inhibition, with the exception of
GlcN-2-SO4.
Covalently bound GlcN-SO4 compounds differentially af-
fect net PG synthesis by chondrocyte cultures. Net PG
synthesis was inhibited by GlcN and the inhibition was
not reversed with the addition of ATP but there was a trend
toward partial reversal with increasing concentrations of in-
osine, from 0.5 to 5.0 mM Fig. 6. Increasing concentrations
of inosine alone, up to 1 mM, resulted in increasing PG
synthesis, compared to controls. The addition of GlcN-2-
SO4, GlcN-2,3-di-SO4, GlcN-2,6-di-SO4, GlcN-6-SO4,
GlcN-3-SO4 all resulted in inhibition of PG synthesis,
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Fig. 5. (A, B) Effects of covalently bound GlcN-SO4 compounds on chondrocyte proliferation and
3H-thymidine incorporation. The test com-
pounds were added a 1 mM concentration under AD culture conditions in Glc-free media, as described in the Methods. For (A) (proliferation),
the cells were enumerated after 4 days of incubation. For (B) (3H-thymidine incorporation into chondrocyte DNA), AD cultures were allowed to
grow for 7 days and then labeled with 3H-thymidine for 18 h, prior to harvesting at 8 days. The radioactivity incorporated into the cells is nor-
malized for 1000 cells in each well. Abbreviations in the ﬁgures for the covalent glucosamine sulfates are GlcN2S ¼GlcN-2-SO4,
GlcN23S¼GlcN-2,3-di-SO4, GlcN26S¼GlcN-2,6-di-SO4, GlcN6S¼GlcN-6-SO4, GlcN3S¼GlcN-3-SO4. Concentrations of inosine are indi-
cated on the ﬁgure and ATP was at 0.625 mM.relative to controls, while GlcN-2,6-di-SO4 did not have an
inhibitory effect. There was no statistically signiﬁcant differ-
ence in the inhibition of net PG synthesis with the addition
of GlcN-3-SO4 when the various concentrations of inosine
were also added. ATP and inosine did not inhibit any
chondrocyte activity or function. GlcN.HCl-mediated inhibi-
tion of cell proliferation and DNA synthesis was not re-
versed by inosine. With simultaneous treatment with
GlcN.HCl and increasing concentration of inosine
(0.5e5 mM), inosine partially removed GlcN.HCl inhibition
on PG synthesis. The PG syntheses are lower than with
inosine treatment alone, but were higher than GlcN.HCl,
suggesting that GlcN.HCl inhibition on PG synthesis may
be related to inadequate energy source. ATP failed to pre-
vent GlcN.HCl or GlcN-3-SO4 associated inhibition of
chondrocyte proliferation and PG synthesis. 2.5 mM ino-
sine completely reversed GlcN-3-SO4 mediated inhibition
on cell proliferation and DNA synthesis. These data indi-
cate that the GlcN-3-SO4 inhibitory effect on cell prolifera-
tion may in part be due to energy depletion, and could be
distinct from those of GlcN.HCl.Discussion
The mechanism by which higher concentrations of GlcN
inhibit PG synthesis and chondrocyte proliferation (Fig. 3)
is not deﬁnitively established. Aminosugars are known to in-
duce apoptosis in tumor cells23. GlcN added in concentra-
tions of 5e20 mM to human chondrocyte cultures showed
a dose-dependent uptake of propidium iodide but there
was limited binding of annexin V24. Our results suggest
a lower number of cells enter the G1 phase, but the mech-
anism of this effect was not investigated and appeared not
to be speciﬁc to GlcN, since dilution of the amino acids and
other nutrients in the media resulted in a decline in the per-
centage of propidium-stained cells. Nevertheless, the ab-
sence of glucose in the medium generally increases the
anti-proliferative, dose-dependent effect of GlcN and
changes the kinetics of the ﬁnal cell densities achieved,
so that the effect of increasing concentrations of GlcN be-
comes essentially linear [Fig. 3(D)]. GlcN, in bovine chon-
drocytes, has been shown to inhibit glucose uptake in
a manner consistent with the actions of a competitive
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Fig. 6. Effects of covalently bound GlcN-SO4 compounds on net PG synthesis by chondrocytes. Experiments were done under AD conditions
in 24-well plates. Chondrocytes were seeded at high density and were conﬂuent within 4 days. Labeling protocol and quantiﬁcation of [35S]-
sulfate incorporation into the medium PGs are described in the Methods. The designations of the added compounds are as in Fig. 6.inhibitor, likely through the GLUT family of facilitative glu-
cose transporters24. The effect of GlcN on glucose transport
probably accounts, at least in part, for the differences in the
kinetics of ﬁnal cell densities achieved, shown in Fig. 3D.
However, some of the exogenously added GlcN entering
the cell may be converted to GlcN-6-P, which is a potent
competitive inhibitor for the Fru-6-P site of the key, rate-lim-
iting, enzyme glutamine-fructose-6-phosphate amidotrans-
ferase (GFAT), which catalyzes the ﬁrst committed step in
the pathway for biosynthesis of hexosamines25. Increased
ﬂux through GFAT has been linked to the enhanced bioac-
tivity of transforming growth factor b1 (TGF-b1)26, so
modulation of endogenous production of TGF-b1 by exoge-
nous GlcN could play a role in controlling chondrocyte
growth. For human chondrocytes cultured as monolayer,
TGF-b can either stimulate or suppress cell growth, de-
pending on conditions, and effects are modulated by inter-
leukin (IL)-127. The stage of culture is also important in
how chondrocytes respond to TGF-b, since de-differentiat-
ing BAC sub-cultured repeatedly on plastic modulate the re-
sponse to TGF-b1 in terms of the PGs they synthesize28.
Also, TGF-b can inﬂuence the relationship between the
amount of PG synthesized per cell and the cell density29.
The addition of a combination of the peptide growth fac-
tors TGF-b1, ﬁbroblast growth factor-2, and platelet-derived
growth factor to human chondrocytes in monolayer culture
increased the rate of proliferation only after the ﬁfth day of
culture, but resulted in a four-fold increase at conﬂuency30.
By contrast, the addition of 0.5 mM GlcN to the chondrocyte
cultures decreased both the rate of proliferation and the ﬁ-
nal cell density achieved, with the effect on the latter prom-
inently seen at day 8, an effect counteracted by the addition
of GlcNAc [Fig. 3(A)], which indicates that there is a critical
effect of N-acetylation of GlcN on chondrocyte kinetics,
for the concentrations of the aminosugars tested. Re-feeding
the GlcN-treated cultures with GlcNAc did not fully reverse
the inhibitory effect of GlcN on the ﬁnal cell density
achieved [Fig. 3(B)], which suggests some persistence of
the GlcN effect over the period tested. These concentrationswould be much higher than achieved in vivo, as discussed
with respect to the PK studies.
In addition to the GFAT pathway, the apoptotic pathway is
also linked to release and activation of TGF-b2 in hypertro-
phic chondrocytes31, and the TGF-b related BMP2 molecule
prevents apoptosis in a chondrocytic cell line through NK-kB
activation32. Thus, while the observed effects of GlcN could
be mediated through the GFAT or the apoptopic pathway,
in either case it appears that modulation of members of the
TGF-b supergene family likely plays a key role.
Our experiments with GlcN.S do not suggest any sub-
stantial difference between this salt of GlcN and GlcN.HCl,
either in terms of behavior on gel ﬁltration chromatography
or on the growth assay [Fig. 4(A, B)]. Further, there is no
chemical basis for expecting that the GlcN moiety itself of
the two salts would behave differently in biological assays.
As indicated in the Introduction, the results for in vitro ef-
fects with different preparations of GlcN or GlcN.S are
highly dependent on the culture system used12e14. A recent
communication with one GlcN.S preparation (Rotta) reports
inhibition of genes induced by IL-1 in human chondrocytes
at very low concentrations of GlcN.S, close to what is found
in plasma33. However, no GlcN.HCl controls were reported,
so it is not clear if these observations are speciﬁc to the
GlcN.S preparation used for that system.
The differential effects of the covalently bound GlcN-SO4
compounds on chondrocyte proliferation were largely deter-
mined by the location of the SO4 substituent on the GlcN
molecule [Fig. 5(A, B)]. This is clearly different than the
GlcN.S salt whose effects were apparently due to the
GlcN moiety itself, as was the case for the GlcN.HCl salt.
For these culture conditions, the addition of GlcN (1 mM)
markedly inhibits chondrocyte proliferation, DNA synthesis
and net PG synthesis [Figs. 5(A, B) and 6]. The GlcN mol-
ecules substituted at the 2-position or 6-position with e SO4
did not show the anti-proliferative effect on cell numbers of
the unsubstituted GlcN molecule [Fig. 5(A)], suggesting that
sulfation of GlcN at the amino group partially reverses the
anti-proliferative effect of the parent molecule, although
955Osteoarthritis and Cartilage Vol. 15, No. 8not to the same extent as does N-acetylation. In general,
the effects on DNA synthesis were more marked than for
cell proliferation, and the inhibitory effects magniﬁed with
the longer period of labeling. However, covalent sulfation
of GlcN, at positions 3 and 6, results in complex effects
on AC proliferation and PG synthesis. None of the sulfated
GlcN analogues were found to have stimulatory effects.
With respect to modulation of the inhibitory effects by the
additions of energy sources (ATP or inosine), the
GlcN.HCl-mediated inhibition of cell proliferation and DNA
synthesis was not reversed by inosine. Simultaneous treat-
ment with GlcN.HCl and increasing concentration of inosine
(0.5e5 mM) partially removedGlcN.HCl inhibition of PG syn-
thesis. The PG syntheses are lower than with inosine treat-
ment alone, but were higher than GlcN.HCl, suggesting that
GlcN.HCl inhibition on PG synthesis may be related to inad-
equate energy source, particularly since 2.5 mM inosine
completely reversed GlcN-3-SO4 mediated inhibition on cell
proliferation and DNA synthesis. These data suggest that
the inhibitory effect of GlcN-3-SO4 on cell proliferation may
in part be mediated through energy depletion, and support
the notion of a distinct mechanism of action from the effects
of GlcN in this system. There is also a possibility that the
GlcN-SO4 derivatives are incorporated into higher glycans
and could modify cell metabolism and function, which would
be of signiﬁcant interest with respect to the emerging ﬁeld of
glycomics for new and improved therapeutics34.
The systematic review of available clinical trials on
GlcN.S has indicated that there was effectiveness of that
preparation (provided by Rotta) for OA of the knee, in stud-
ies conducted largely in Europe1. However, the recent,
large, NIH supported, American clinical trial (GAIT) showed
no effect of GlcN.HCl for OA of the knee and demonstrated
a large placebo response35. A recent report, in abstract
form, of the European trial (Glucosamine Unum in Die Efﬁ-
cacy Trial) showed improvement in quality of life measures,
which correlated with improvement in pain and function
scores36. These studies assessed primarily pain reported
and scored by the patient on a scale. The opposing clinical
conclusions with the two preparations, used in these trials,
have not been explained and the controversy continues as
to whether GlcN is effective for OA of the knee. Although
there are a number of reasons (including clinical methodol-
ogy, study biases, etc.) that could account for the differ-
ences in these studies, the possibility exists that the
differences found are due to the preparations themselves.
From a biochemical and pharmacological perspective one
would expect that after ingesting either the GlcN.HCl or
the GlcN.S salt, the same molecule, namely GlcN, would
enter the circulation and be delivered to the tissues. A
blinded clinical trial directly comparing the PKs of an ac-
cepted GlcN.S preparation against GlcN.HCl would be re-
quired to demonstrate this point in human subjects. Also,
there is a possibility that some GlcN.S preparations could
contain small amounts of a contaminant(s) with another bi-
ological activity, but this has not been demonstrated. In the
assay systems we describe, the GlcN.HCl and GlcN.S
salts, obtained in high purity, behaved essentially identi-
cally, while the behavior of the GlcN.S salt was distinctly dif-
ferent than that of the covalently bound GlcN-SO4
compounds.
Attempts to correlate in vitro results with PK studies and
clinical efﬁcacy face severe limitations. In particular, the
choice of the cell culture system for comparative drug eval-
uation can affect not only the chondrocyte phenotype but
also the magnitude of the response (output) to the drug be-
ing tested. The importance of culture conditions has beenrecently emphasized for chondrocyte proliferation, matrix
synthesis and gene expression37. This is illustrated by com-
paring Fig. 1A and B (the alginate bead, AI system) with
Fig. 1C (the monolayer, AD system) for net synthesis of
PG with increasing GlcN concentrations. Thus, although
the AI system, consisting of freshly isolated BAC set up in
the alginate beads, showed the cartilage-speciﬁc FN iso-
form (VþC) to be predominant, and no detectable type I
collagen expression, it is a less sensitive system for inves-
tigating proliferative responses of chondrocytes with varying
GlcN concentrations. Also, the complexity of the alginate
2-compartment system (bead and medium) is illustrated in
Fig. 1A and B. Further, the deeper cells within the bead
almost certainly are exposed to quite different concentra-
tions of the added GlcN than cells in the superﬁcial part of
the bead, although little speciﬁc information is available
for concentration gradients within this type of AI system.
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